Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL
Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: onclive.com
Page 31 - Cll News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cll Today - Breaking & Trending Today
Increased Understanding of CLL Tumor Biology Unlocks Targeted CAR T-Cell Approaches
Jan Joseph Melenhorst, PhD, emphasizes how research investigating chronic lymphocytic leukemia biology may result in more targeted CAR T-cell products.
Source: onclive.com
Liso-Cel Maintains Longer-Term Responses in Pretreated Relapsed/Refractory CLL/SLL
Tatyana Feldman, MD, highlights updated data for liso-cel in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Source: onclive.com
Expert Insights into Investigation Therapies for CLL
Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.
Source: onclive.com
Mass-Like Opacities on Imaging Linked With LPI in CLL
Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found.
Source: ajmc.com